Najnowsze wersje próbne


EudraCT Number: 2022-002407-37 Sponsor Protocol Number: BET-PSMA-121 Start Date: 2023-05-22
Sponsor Name: Blue Earth Therapeutics Limited
Full Title: An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with met...
Medical condition: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
Disease: Version SOC Term Classification Code Term Level
21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
Population Age: Adults, Elderly Gender: Male
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-001781-35 Sponsor Protocol Number: UKER-BC007-01 Start Date: 2023-05-16
Sponsor Name: Universitätsklinikum Erlangen
Full Title: Prospective, explorative, randomized, controlled, double-blind, cross-over phase IIa clinical trial to investigate safety and tolerability as well as potential clinical effects of BC007 in patients...
Medical condition: Post-COVID syndrome
Disease: Version SOC Term Classification Code Term Level
24.0 100000004862 10085505 Post-COVID syndrome LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003865-39 Sponsor Protocol Number: WSG-AM12 Start Date: 2023-05-04
Sponsor Name: Westdeutsche Studiengruppe GmbH
Full Title: NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+pertuzumab in HER2+ early breast cancer
Medical condition: HER2+ early breast cancer
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006192 Breast cancer NOS LLT
23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
Population Age: Adults, Elderly Gender: Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2023-000033-33 Sponsor Protocol Number: 83631 Start Date: 2023-05-03
Sponsor Name: Maastricht University
Full Title: Short-term safety and efficacy of ketohexokinase inhibition in patients with hereditary fructose intolerance.
Medical condition: Hereditary fructose intolerance
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10019878 Hereditary fructose intolerance PT
20.1 10010331 - Congenital, familial and genetic disorders 10017397 Fructose intolerance hereditary LLT
21.0 10027433 - Metabolism and nutrition disorders 10072104 Fructose intolerance PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003056-14 Sponsor Protocol Number: VTX958-203 Start Date: 2023-05-03
Sponsor Name: Ventyx Biosciences, Inc
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Patients with Active Psoriatic Arthritis
Medical condition: Active Psoriatic Arthritis
Disease: Version SOC Term Classification Code Term Level
21.0 100000004859 10037160 Psoriatic arthritis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) CZ (Ongoing) ES (Ongoing) HU (Ongoing) BG (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003452-14 Sponsor Protocol Number: SBC007C401 Start Date: 2023-05-02
Sponsor Name: Berlin Cures GmbH
Full Title: A prospective, double-blind, randomised, parallel group, placebo controlled, multicentre, Phase II study to investigate the efficacy, GPCR autoantibody neutralising effect, safety, and tolerability...
Medical condition: long Covid
Disease: Version SOC Term Classification Code Term Level
25.1 100000004862 10087832 COVID-19 rebound LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) FI (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-005551-36 Sponsor Protocol Number: NL79416.018.21 Start Date: 2023-05-01
Sponsor Name: Amsterdam University Medical Center, AMC
Full Title: Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock from Acute Myocardial Infarction: A Multicenter Randomized...
Medical condition: Myocardial infarction related cardiogenic shock
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003866-19 Sponsor Protocol Number: 83336 Start Date: 2023-05-01
Sponsor Name: Amsterdam UMC location AMC
Full Title: The effect of low-dose rhythmic 17-β-estradiol administration on bone turnover in postmenopausal women
Medical condition: Osteoporosis prevention
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003810-35 Sponsor Protocol Number: BMX-04-001 Start Date: 2023-04-25
Sponsor Name: BiomX Ltd.
Full Title: A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomon...
Medical condition: Cystic fibrosis Chronic Pseudomonas Aeruginosa Infection
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
22.1 100000004862 10082869 Chronic Pseudomonas aeruginosa infection LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing) CZ (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003408-33 Sponsor Protocol Number: ESR-21-21536 Start Date: 2023-04-25
Sponsor Name: TheraOp gGmbH
Full Title: PACCELIO - FDG-PET based small volume accelerated immuno chemoradio-therapy in locally advanced NSCLC
Medical condition: Locally advanced, unresectable non-small-cell lung cancer (NSCLC) (Stage III) with a PD-L1-expression of ≥ 1%
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)